Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PLEC | Q15149 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9251955 | 0.82 | MAPT (0.66) | PTGER4ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL15774530 | 0.81 | PTGER4 (1.00) | PTGER4ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL22135331 | 0.79 | PRSS1 (0.59) | PTGER4ALDH1A1GAAMAPTKDM4E | |
| SCHEMBL9525197 | 0.79 | KDM4E (0.72) | PTGER4ALDH1A1SMN1; SMN2GAAMAPT | |
| SCHEMBL3951255 | 0.79 | SMN1; SMN2 (0.66) | ALDH1A1SMN1; SMN2GAAMAPTKDM4E | |
| SCHEMBL9360969 | 0.78 | HDAC3 (0.58) | ALDH1A1SMN1; SMN2GAAMAPTHTT | |
| SCHEMBL11571129 | 0.78 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2GAAHPGDHTT | |
| Hydrochloric Acid SCHEMBL9252446 | 0.78 | MAPT (0.67) | PTGER4ALDH1A1SMN1; SMN2GAAMAPT | |
| Hydrochloric Acid SCHEMBL2947137 | 0.77 | SMN1; SMN2 (0.64) | ALDH1A1SMN1; SMN2GAAMAPTKDM4E | |
| SCHEMBL14094315 | 0.77 | ALDH1A1 (0.67) | PTGER4ALDH1A1SMN1; SMN2GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2007133983-A2 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | PHARMACOPEIA, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071130-A1 | 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES | ADORA2A, ADORA2B, ADORA1 | PTGER4 710/4885ALDH1A1 521/4885SMN1; SMN2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.